Don't show this message again
42 U.S. Code § 287a. Cures Acceleration Network
(a) DefinitionsIn this section:
(1) Biological product
The term “biological product” has the meaning given such term in section 262 of this title.
(2) Drug; device
The terms “drug” and “device” have the meanings given such terms in section 321 of title 21.
(3) High need cureThe term “high need cure” means a drug (as that term is defined by section 321(g)(1) of title 21,[1] biological product (as that term is defined by section 262(i) [2] of this title), or device (as that term is defined by section 321(h) of title 21) that, in the determination of the Director of the Center—
(A)
is a priority to diagnose, mitigate, prevent, or treat harm from any disease or condition; and
(B)
for which the incentives of the commercial market are unlikely to result in its adequate or timely development.
(4) Medical product
The term “medical product” means a drug, device, biological product, or product that is a combination of drugs, devices, and biological products.
(b) Establishment of the Cures Acceleration NetworkSubject to the appropriation of funds as described in subsection (g), there is established within the Center a program to be known as the Cures Acceleration Network (referred to in this section as “CAN”), which shall—
(1)
be under the direction of the Director of the Center, taking into account the recommendations of a CAN Review Board (referred to in this section as the “Board”), described in subsection (d); and
(2)
award grants and contracts to eligible entities, as described in subsection (e), to accelerate the development of high need cures, including through the development of medical products and behavioral therapies.